Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons through 5-HT1A receptor partial agonism and &#945;1-adrenoceptor antagonism by Montalbano, A. et al.
RESEARCH ARTICLE
Dual inhibitory action of trazodone on dorsal
raphe serotonergic neurons through 5-HT1A
receptor partial agonism and α1-adrenoceptor
antagonism
Alberto Montalbano1, Boris Mlinar1, Francesco Bonfiglio1, Lorenzo Polenzani2,
Maurizio Magnani2, Renato CorradettiID1*
1 NEUROFARBA—Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino,
Università di Firenze, Firenze, Italia, 2 Angelini RR&D (Research, Regulatory & Development), Angelini S.p.
A, S.Palomba-Pomezia (Roma), Italia
* renato.corradetti@unifi.it
Abstract
Trazodone is an antidepressant drug with considerable affinity for 5-HT1A receptors and α1-
adrenoceptors for which the drug is competitive agonist and antagonist, respectively. In this
study, we used cell-attached or whole-cell patch-clamp recordings to characterize the
effects of trazodone at somatodendritic 5-HT1A receptors (5-HT1AARs) and α1-adrenocep-
tors of serotonergic neurons in rodent dorsal raphe slices. To reveal the effects of trazodone
at α1-adrenoceptors, the baseline firing of 5-HT neurons was facilitated by applying the
selective α1-adrenoceptor agonist phenylephrine at various concentrations. In the absence
of phenylephrine, trazodone (1–10 μM) concentration-dependently silenced neurons
through activation of 5-HT1AARs. The effect was fully antagonized by the selective 5-HT1A
receptor antagonist Way-100635. With 5-HT1A receptors blocked by Way-100635, trazo-
done (1–10 μM) concentration-dependently inhibited neuron firing facilitated by 1 μM phen-
ylephrine. Parallel rightward shift of dose-response curves for trazodone recorded in higher
phenylephrine concentrations (10–100 μM) indicated competitive antagonism at α1-adreno-
ceptors. Both effects of trazodone were also observed in slices from Tph2-/- mice that lack
synthesis of brain serotonin, showing that the activation of 5-HT1AARs was not mediated by
endogenous serotonin. In whole-cell recordings, trazodone activated 5-HT1AAR-coupled G
protein-activated inwardly-rectifying (GIRK) channel conductance with weak partial agonist
efficacy (~35%) compared to that of the full agonist 5-CT. Collectively our data show that
trazodone, at concentrations relevant to its clinical effects, exerts weak partial agonism at 5-
HT1AARs and disfacilitation of firing through α1-adrenoceptor antagonism. These two
actions converge in inhibiting dorsal raphe serotonergic neuron activity, albeit with varying
contribution depending on the intensity of α1-adrenoceptor stimulation.
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Introduction
The brain serotonin (5-HT) system modulates a variety of brain functions including mood,
cognition, emotional behaviour, and sleep [1, 2, 3] and its dysregulation appears to contribute
in related psychopathological states such as depression, anxiety, impulsivity and aggression
[4].
Trazodone is an antidepressant drug that, in addition to its inhibitory activity at cell mem-
brane 5-HT transporter (SERT), is a competitive ligand at 5-HT1A 5-HT2A, 5-HT2C receptors
and α1-adrenoceptors for which it displays considerable affinity [5, 6]. Although these pharma-
cological properties have been suggested to contribute a favourable safety profile such as facili-
tation of sleep and reduced sexual dysfunction [7], the direct effects of trazodone on
serotoninergic neuron activity are still not adequately known for modelling the possible phar-
macological mechanisms underlying the therapeutic action(s) of the drug.
In the dorsal raphe nucleus (DRN) the spontaneous activity of serotonergic neurons is max-
imally facilitated during wake by noradrenergic input via α1-adrenoceptor stimulation [8] and
activation of 5-HT system contributes to arousal [9, 10]. Under these conditions, the firing of
serotonergic neurons is tonically limited via the stimulation of somatodendritic 5-HT1A auto-
receptors (5-HT1AARs) exerted by the endogenous 5-HT present in the extracellular space sur-
rounding serotonergic neurons [11, 12]. However, increased extracellular 5-HT in raphe
nuclei acutely produced by block of SERT results in (auto)inhibition of serotonergic neuron
activity and consequently in reduction of 5-HT release in projection brain areas. This is
believed to delay the onset of antidepressant therapeutic effect until subsensitivity of
5-HT1AARs develops to weaken the autoinhibitory feedback [13, 14]. On the basis of this
notion it has been proposed that the association of 5 HT1A receptor antagonists could hasten
the response to monoamine uptake blockers [15, 16, 17] and, more recently, that antidepres-
sant drugs with partial agonist property at 5 HT1A receptors could display faster onset of thera-
peutic response [18].
In vivo recording of serotonergic neuron activity in anaesthetized rats showed that acute
administration of trazodone inhibits DRN serotonergic neuron firing [19] an action mediated
by activation of somatodendritic 5-HT1AARs which desensitize after chronic treatment with
the antidepressant drug [20]. Nevertheless, the direct functional effects of trazodone on
5-HT1AARs are still insufficiently characterized to establish whether the drug exerts full or par-
tial agonism at 5-HT1AARs. In the rat, in a functional assay in vitro trazodone was found to
activate [35S]GTPγS binding with weak efficacy [21], while in vivo its action on serotonergic
neuron firing appeared consistent with stronger agonism at 5-HT1AARs [22].
The interplay between the 5-HT1A receptor agonist activity and α1-adrenoceptor antagonist
activity of trazodone at the level of serotonergic neurons likely plays a crucial role in regulating
the firing of serotonergic neurons, hence the release of 5-HT in projection areas during acute
and chronic administration of the drug. Actually, a strong noradrenergic input to the dorsal
and other raphe nuclei has been identified [23, 24] which tonically activates raphe serotonergic
neurons through postsynaptic α1-adrenoceptors [25]. Therefore, the α1-adrenoceptor antago-
nist properties of trazodone could participate to the inhibiton of DRN serotonergic neuron fir-
ing by reducing the noradrenergic drive, but experiments in vivo were unable to quantify this
action in the DRN in conditions in which trazodone appeared to have α1-adrenoceptor block-
ing effects in the hippocampus [22].
In the present work we designed in vitro experiments directed to quantify the agonist effi-
cacy of trazodone at 5-HT1AARs of DRN serotonergic neurons and to establish the possible
effect of α1-adrenoceptor antagonism. Here we show that trazodone exerts weak partial agonist
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action at 5-HT1AARs and α1-adrenoceptor antagonism at low micromolar concentrations that
are relevant to the therapeutic effects of the drugs.
Materials and methods
Animals and animal care
Animal care and experimental procedures strictly complied with the European Communities
Council Directive (2010/63/UE) and were approved by the Italian Ministry of Health (Aut:
224/2017-PR and 938/2017-PR). Every effort was made to reduce the number of animals used.
Male Wistar rats were purchased from Envigo Italy (Milan, Italy). Tryptophan hydroxylase-2
knock-out (Tph2-/-) mice were obtained from Prof. K.P. Lesch (University of Wu¨rzburg,
Wu¨rzburg, Germany). Animals were housed on a 12:12 h day-night cycle with food and water
ad libitum.
Procedures for tissue isolation, slice superfusion and electrophysiological recording from
DRN serotonergic neurons of rat and mouse have been previously described in detail [26, 27,
28].
Preparation of brain slices
Slices were prepared from animals aged 4–10 weeks (4–5 weeks for whole-cell patch-clamp
recordings). Animals were deeply anesthetized with isoflurane and decapitated. Brains were
rapidly removed and dissected in ice-cold gassed (95% O2 and 5% CO2) artificial cerebrospinal
fluid (ACSF) composed of: 124 mM NaCl, 2.75 mM KCl, 1.25 mM NaH2PO4, 1.3 mM MgCl2,
2 mM CaCl2, 26 mM NaHCO3, 11 mM D-glucose. The brainstem was sliced coronally into
200 μm thick slices with a vibratome (DSK, T1000, Dosaka, Japan). After recovery for at least
90 min at room temperature, the slices were individually transferred to the recording chamber
and superfused continuously, at a rate of 2 ml min-1, with warmed ACSF (Warner Instruments
in-line heater TC324-C). Slices were allowed to equilibrate for at least 15 min before the begin-
ning of the recording. Drugs were bath-applied through a peristaltic pump-driven perfusion
system and a complete exchange of the recording chamber volume occurred in approximately
1 min. Neurons within DRN were visualized by infrared differential interference contrast
(IR-DIC) video microscopy with a Newicon camera (C2400-07; Hamamatsu, Hamamatsu
City, Japan) mounted on an upright microscope (Axioskop; Zeiss, Go¨ttingen, Germany).
Recordings were made using an EPC-10 amplifier (HEKA Elektronic, Lamberecht, Germany).
Patch pipettes were prepared from thick-walled borosilicate glass on a P-97 Brown-Flaming
electrode puller (Sutter Instruments, Novato, CA, USA). Data were analyzed using Patchmas-
ter 2 (HEKA Elektronic), Clampfit 9.2 (Molecular Devices, Sunnyvale, CA, USA) and Prism 7
software (GraphPad Software, San Diego, CA, USA).
Electrophysiology
Action potential firing activity of serotonergic neurons was recorded by loose-seal cell-
attached recordings at a temperature of 34–36˚C. To reproduce in slices the noradrenergic
drive which facilitates serotonergic neuron firing during wakefulness [8]), ACSF was supple-
mented with the α1-adrenoceptor agonist phenylephrine (PE, 10 μM, unless otherwise stated).
In a set of experiments neuron firing was facilitated in an α1-adrenoceptor–independent mode
using a modified ACSF containing low Ca2+ (0.67 mM), high K+ (5.5 mM) and no PE. When
appropriate, ACSF contained a “cocktail” of glutamate GABA/glycine and adenosine A1 recep-
tor blockers consisting of: 10 μM NBQX (2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]qui-
noxaline-7-sulfonamide disodium salt), 20 μM d-AP5 (d-(-)-2-amino-5-phosphonopentanoic
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acid), 10 μM SR-95531 (6-imino-3-(4-methoxyphenyl)-1(6H)-pyridazinebutanoic acid hydro-
bromide), 2 μM CGP-55845 (3-N[1-(S)-(3,4-dichlorophenyl)ethyl]amino-2-(S)-hydroxypro-
pyl-P-benzyl-phosphinic acid hydrochloride) and 10 μM strychnine hydrochloride, 0.2 μM
DPCPX (8-Cyclopentyl-1,3-dipropylxanthine) to functionally isolate the recorded neuron
from major synaptic input. Patch pipettes were prepared from thick-walled borosilicate glass
on a P-97 Brown-Flaming electrode puller (Sutter Instruments, Novato, CA, USA) and had
resistances of 3–6 MO when filled with solution containing (in mM): 125 NaCl, 10 HEPES,
2.75 KCl, 2 CaCl2, 1.3 MgCl2 (pH 7.4 with NaOH). Loose-seal cell-attached recordings (5–20
MO seal resistance) were acquired continuously in the voltage-clamp mode. Signals were fil-
tered at 3 kHz and digitized at 10 kHz. The firing rate was reported using 10 s bins. Data were
analysed using Clampfit 9.2 (Molecular Devices, Sunnyvale, CA, USA). Most recorded neu-
rons were located in the dorsal and ventromedial part of the DRN. Neurons were identified
according to electrophysiological criteria [12, 29]. Only neurons with a stable baseline firing
rate were used.
Methods used for measuring G protein-activated inwardly-rectifying (GIRK) channel con-
ductance have been detailed previously [12, 27]. All experiments were performed in ACSF sup-
plemented with a cocktail of neurotransmitter blockers (see above). ACSF contained 5.5 mM
K+ to increase the driving force for inward potassium current (the additional 2.75 mM by Na+
substitution). Recording pipettes had a resistance of 2–5 MO. The pipette solution consisted
of: 120 mM K-gluconate, 15 mM KCl, 2 mM MgCl2, 10 mM HEPES, 0.1 mM EGTA, 10 mM
Na2phosphocreatine, 4 mM MgATP, 0.3 mM Na3GTP (pH 7.35 with KOH). After establishing
whole-cell recording configuration, serotonergic neurons were identified on the basis of
electrophysiological properties displayed in current-clamp mode (action potential half-height
width> 1.1 ms; absent or very small fast afterhyperpolarization; sustained repetitive firing in
response to depolarizing current injection). In current-clamp recordings signals were filtered
at 5 kHz and digitized at 25 kHz. To estimate inwardly-rectifying K+ conductance, we used
hyperpolarizing voltage ramps from the holding potential of -65 mV (to -125 mV, every 10 s;
100 mV s-1; 3 kHz cutoff frequency low-pass filter; 10 kHz sampling frequency) and measured
the conductance from the slope of inward K+ current in the range from -110 to -85 mV (G-
110/-85 mV). To monitor access resistance throughout the recording, hyperpolarizing pulses (10
mV; 100 ms duration; 16 kHz low-pass filter; 25 kHz sampling frequency; cell capacitance can-
cellation circuit switched off) were interlaced with ramps. Access resistance was not compen-
sated and when it was higher than 25 MO recordings were discarded. Concentration–response
curves for trazodone were obtained using a cumulative protocol in which increasing concen-
trations were applied in 7–10 min intervals as appropriate. Average of 7 consecutive individual
ramps, corresponding to the segment with the maximal effect for the given trazodone concen-
tration were used to obtain conductance values. To calculate net 5-HT1AAR-activated GIRK
current and conductance (G5-HT1A) present during a recording, the 5-HT1AAR-insensitive
current was measured at the end of a recording following application of the selective 5-HT1A
receptor antagonist Way-100635 (20 nM; 10–15 min) and subtracted from the total current.
Calculation of concentration-response relationships
For creating cumulative concentration-response curves for trazodone, the drug was applied
for 10–30 min (as appropriate for the specific experimental objective) and mean firing rates
were calculated from the last one-minute segment of each experimental epoch (e.g. baseline,
trazodone 0.3 μM, 1 μM, etc.). Trazodone dose-response relationship for suppression of sero-
tonergic neuron firing was computed by fitting data to the logistic equation b + (a—b) / (1 +
(EC50 / [trazodone])nH), where EC50 is the half-maximally effective concentration, nH is the
Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons
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Hill coefficient, a is the baseline firing rate and b is the fraction remaining at the maximal traz-
odone effect. Fitting of average dose-response relationship of normalized firing rate: for each
experiment, firing rate was measured during the last 2 min of drug application for each con-
centration and normalized by taking the pre-drug baseline firing rate as unity. Then the rela-
tionship for suppression of serotonergic neuron firing was computed by fitting mean values (±
SD) for each concentration to the logistic equation, b + (1—b) / (1 + (EC50 / [trazodone])nH),
where EC50 is the half-maximally effective concentration, nH is the Hill coefficient and b is the
fraction remaining at the maximal trazodone effect.
The respective fractional occupancy of 5-HT1A receptors by trazodone and the full agonist,
either 5-carboxamidotryptamine (5-CT) or 5-HT, in the presence of trazodone was calculated
using the Gaddum equation: [AR]/Rt = [A]/([A]+Ka(1+[B]/Kb)), where [AR]/Rt is the frac-
tional occupancy by the full agonist, [A] is the concentration of the full agonist with Ka affinity
constant and [B] and Kb are trazodone concentration and affinity, respectively. To allow com-
parison of theoretical values with the responses experimentally obtained in rat serotonergic
neurons, we calculated the occupancies for 5-CT and trazodone by applying the Ki of the two
agonists for the rodent 5-HT1A (5-CT: Ki = 0.325 nM, [30]; trazodone: Ki = 42 nM, [5]). For
the action of trazodone on 5-HT we used the Ki of the two agonists for the human 5-HT1A
receptor (5-HT: Ki = 3.98 nM, [31, 32]; trazodone: Ki = 96 nM, [6]) to allow inference on the
effects of trazodone on responses to endogenous 5-HT in vivo.
In both cases, the expected total activation of GIRK conductance was calculated from the
respective occupancies of the two compounds by using the measured maximal efficacy of 0.35
for trazodone and 1.0 for the full agonist.
Drugs
Trazodone was provided by A.C.R.A.F. S.p.A. (Santa Palomba, Rome). 5-HT, SR-95531, D-
AP5, NBQX were purchased from Ascent Scientific Ltd. (Bristol, UK). Way-100635 maleate,
CGP-55845 hydrochloride, 5-CT and DPCPX were purchased from Tocris Bioscience (Bristol,
UK). L-Phenylephrine and strychnine hydrochloride from Sigma-Aldrich S.r.l. (Milan, Italy).
Statistical analysis
Data are presented as geometric mean and confidence interval (C.I.) or mean ± SD as appro-
priate. Statistical comparisons were performed by ANOVA followed by Tukey post-hoc test,
paired or unpaired t-test (two tailed), as appropriate. Pearson test was used to assess for corre-
lation between variables. All the statistical tests were performed by GraphPad Prism version 7.
Throughout the analyses, statistical significance was taken as p< 0.05.
Results
Concentration-dependent inhibition of serotonergic neuron firing by
trazodone is mediated by more than one action
Application of trazodone produced a concentration-dependent inhibition of DRN serotoner-
gic neuron activity facilitated by 10 μM PE in standard ACSF (Fig 1A and 1B).
The effect of trazodone was partially antagonized by the selective 5-HT1A receptor antago-
nist Way-100635. Trazodone silenced neurons with a mean of EC50 values = 1.78 μM (Geo-
metric mean, GM, 95% Confidence Interval, 95% C.I.: 1.165–2.713, n = 11; Fig 1C). In a subset
of experiments in which Way-100635 (20 nM) was added to 10 μM trazodone, the firing rate
recovered to less of 50% relative to baseline firing rate (47.54 ± 21; 41%; n = 7; Fig 1D) suggest-
ing that trazodone effect was only in part mediated by activation of 5-HT1AARs.
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The non 5-HT1AAR-mediated decrease in firing of serotonergic neurons produced by traz-
odone could indirectly be elicited by changes in the release of GABA, glycine or adenosine
from neighbour neurons, or glutamate from terminals. We therefore carried out a set of exper-
iments in ACSF containing a “cocktail” of receptor antagonists for major neurotransmitters
(see methods).
Under these conditions, the inhibitory effect of trazodone was very similar to that exerted
in standard ACSF (Fig 1E–1H). The average EC50 value was 1.77 μM (GM, 95% C.I.: 1.023–
3.034, n = 11). Statistical comparison of EC50 values in individual neurons revealed no differ-
ences of trazodone effect in standard ACSF and cocktail ACSF (unpaired t test, two tails:
t = 0.2813; df = 20; p = 0.7814). Similar to the previous set of experiments, in a subset of experi-
ments in which Way-100635 (20 nM) was added to 10 μM trazodone, the firing rate recovered
to 45.93 ± 30.32% (n = 6, Fig 1H) of baseline firing rate. These results demonstrate that the
Way-100635-insensitive inhibitory effect trazodone was directly exerted on serotonergic neu-
rons and not mediated by release of GABA, glycine, adenosine and glutamate from the local
Fig 1. The inhibition of 5-HT neuron activity by trazodone. (A-D): Effect of trazodone (TZD) in control ACSF. (A) Representative recording illustrating the time-
course of the changes in firing frequency produced by increasing concentrations of trazodone. The maximal effect was partially reversed by the selective 5-HT1A
receptor antagonist Way-100635 (20 nM). (B) Dose-response curve (DRC) resulting from the experiment shown in (A). Red line is the best least-squares fit to the
logistic equation. (C) Scatter plot of the individual EC50 values calculated from all experiments (n = 11). (D) Antagonism of trazodone (10 μM) effect by addition of
Way-100635 (+Way; n = 7; One-way RM ANOVA: F(2,6) = 107.6; p<0.0001) in the subset of experiments in which Way was added at the end of the DRC, e.g. in (A).
(E-H): Effect of trazodone in a cocktail of antagonists (see methods). (E) Representative recording of the concentration-dependent changes in firing frequency
produced by trazodone. The effect of 10 μM trazodone was partially reversed by Way-100635 (20 nM). Note the recovery of firing rate in Way-100635 after the
washout of trazodone. (F) DRC resulting from the experiment shown in (E). Red line is the best least-squares fit to the logistic equation. (G) Scatter plot of the
individual EC50 values calculated from all experiments (n = 11). (H) Antagonism of trazodone (10 μM) effect by Way-100635 (+Way; n = 6; One-way RM ANOVA:
F(2,5) = 28.68; p<0.0014) in the subset of experiments in which Way was added at the end of the DRC, e.g. in (A). In (B) and (F), dotted line indicates the baseline
(Bsl) firing rate before application of trazodone. In (C) and (G), red line and error bars indicate the geometric mean and 95% C.I. In all experiments the activity of
serotonergic neurons was facilitated by the presence of 10 μM phenylephrine. � p< 0.05; �� p< 0.01; ��� p< 0.001 (One-way RM ANOVA, followed by a Tukey
post-hoc test).
https://doi.org/10.1371/journal.pone.0222855.g001
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network of neurons and terminals. Nevertheless, all subsequent experiments were performed
in the presence of synaptic antagonists.
Trazodone directly activates 5-HT1A receptors in Tph2
-/- mice
To ascertain whether the inhibition of serotonergic neuron firing by trazodone was due to
direct stimulation of 5-HT1AARs or was indirectly mediated by a possible raise in extracellular
5-HT caused by SERT inhibition produced by the drug, we repeated these experiments in
Tph2-/- mice that lack synthesis of brain 5-HT [33]). In this set of experiments 20 nM Way-
100635 was added to the trazodone concentration that produced more than 90% inhibition of
neuron firing (Fig 2A).
In the nine neurons tested, serotonergic neuron firing was silenced at concentrations�
10 μM with an average EC50 value of 0.66 μM (GM, 95% C.I.: 0.3157–1.364, n = 9; Fig 2C). As
shown in Fig 2A and 2B, in four neurons in which 1 μM trazodone decreased the firing by
96.1 ± 7.3%, the effect was fully antagonized by Way-100635. When 10 μM trazodone was
required to silence the recorded neurons, Way-100635 significantly, but only partially, antago-
nized the effect that recovered by 40.13 ± 6.74% (n = 5, Fig 2B). These results confirmed that
trazodone was a direct agonist at 5-HT1AARs. The greater potency of trazodone in inhibiting
firing (EC50 = 0.66 μM) compared to that observed in rat (EC50 = 1.77 μM) is likely to be
ascribed to the supersensitivity of 5-HT1AARs in Tph2-/- mice compared to Tph2+/+ mice (~2,5
folds) [34].
The non 5-HT1A receptor-mediated effect of trazodone depends on α1-
adrenoceptor activation and is competitively surmounted by the α1-
adrenoceptor agonist phenylephrine
The experiments reported in 3.1 and 3.2 show that trazodone inhibits the firing of serotonergic
neurons by direct activation of 5-HT1AARs and that an additional inhibitory effect of the drug
contributes in silencing firing. As trazodone is an α1-adrenoceptor ligand and in our experi-
ments the activity of serotonergic neurons was facilitated by the presence of 10 μM PE, the
non 5-HT1A receptor-mediated inhibitory effect of trazodone could result from disfacilitation
of neuron firing produced by α1-adrenoceptor antagonism.
In preparations in which the neuron firing was facilitated by a low concentration of PE
(1 μM) in the presence of Way-100635 (20 nM), the application of 10 μM trazodone silenced
the neurons and the effect was fully reversed by the addition of 100 μM PE (Fig 3A and 3B;
n = 5).
This showed that the non 5-HT1A receptor-mediated effect of trazodone could be sur-
mounted by increasing PE concentration, indicating that trazodone was acting as competitive
antagonist at α1-adrenoceptors. Accordingly, when the firing was facilitated by low calcium/
high potassium ACSF (see methods) in the absence of PE, trazodone 10 μM produced a pure
5-HT1A receptor-mediated inhibition of serotonergic neuron activity (Fig 3C and 3D).
To better characterize the contribution of α1-adrenoceptor antagonism in the inhibition of
serotonergic neuron firing by trazodone, we compared the concentration-dependent effect of
trazodone in preparations where the firing was facilitated by different concentrations of PE (1,
10, 100 μM) in the presence of 20 nM Way-100635 to block the 5-HT1A receptor-mediated
effect of trazodone (Fig 4).
In PE 1 μM, trazodone concentration-dependently suppressed neuron firing (Fig 4A and
4B) with an average EC50 value of 1.985 μM (GM, 95% C.I.: 1.451–2.716, n = 15; Fig 4C).
When neurons were activated by PE 10 μM the average EC50 value was increased to 9.881 μM
(GM, 95% C.I.: 7.284–13.40, n = 11; Fig 4D–4F). As illustrated in Fig 4G, in PE 100 μM we
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applied only 10 and 30 μM trazodone to avoid a likely contamination of responses by aspecific
effects of the drug at higher concentrations. From this set of experiments (n = 9) individual
EC50 values could not be calculated, while the mean effects for these two drug concentrations
were sufficient to obtain the EC50 value for trazodone effect in 100 μM PE (39.07 μM) from the
calculated average concentration-response curve. Fig 4H illustrates the rightward shift of con-
centration-response curves for the α1-adrenoceptor-mediated inhibitory effect of trazodone
produced by increasing the concentration of PE from 1 μM to 100 μM.
Based on the experiments shown in Fig 4, in the presence of PE 100 μM the contribution of
α1-adrenoceptor antagonism in the overall inhibitory effect at concentrations of trazodone up
to 10 μM was small (12 ± 8% see Fig 4G). We therefore sought to evaluate the potency of trazo-
done in suppressing serotonergic neuron firing through 5-HT1AAR stimulation in these
Fig 2. Effect of trazodone in Tph2-/- mice. (A) Representative recording of concentration-dependent effect of
trazodone (TZD). The effect was fully antagonized by 20 nM Way-100635. (B) Summary of the antagonism exerted by
20 nM Way-100635 (+Way) on responses to 1 μM (n = 4; One-way RM ANOVA: F(2,3) = 36.24; p<0.0045) and 10 μM
(n = 5; One-way RM ANOVA: F(2,4) = 41,95; p<0.0028) trazodone. Note the partial antagonism of responses to 10 μM
trazodone. (C) Scatter plot of the individual EC50 values calculated from all experiments (n = 9). Red line and error
bars indicate the geometric mean and 95% C.I.. The activity of serotonergic neurons was facilitated by the presence of
10 μM PE. � p< 0.05; �� p< 0.01 (One-way RM ANOVA, followed by a Tukey post-hoc test).
https://doi.org/10.1371/journal.pone.0222855.g002
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conditions (i.e. in PE 100 μM) in which the α1-adrenoceptor antagonism by the drug was min-
imized. As shown in Fig 5A and 5B, trazodone inihibited the activity of neurons in a concen-
tration-dependent manner and the effect was completely antagonized by the addition of Way-
100635 (20 nM; Fig 5A and 5E).
The average dose-response relationship calculated on the mean response of nine experi-
ments, is reported in Fig 5C. In eight neurons in which individual EC50 could be calculated the
average EC50 value was of 4.365 μM (GM, 95% C.I.: 2.553–7.466, n = 8; Fig 5D). Notably, the
curve shown in Fig 5C suggested that the agonism of trazodone at 5-HT1AARs was partial.
Nevertheless, due to the residual interference of α1-adrenoceptor antagonism by trazodone at
concentrations > 10 μM the efficacy of the drug at 5-HT1AARs was impossible to be reliably
quantified.
Trazodone activates 5-HT1A autoreceptor-coupled GIRK channels in
serotonergic neurons with weak partial agonist action
To clarify whether trazodone was a partial agonist, we investigated the potency and the func-
tional effect of trazodone at 5-HT1AARs of rat DRN serotonergic neurons recorded in whole-
cell configuration. To this purpose, we measured the changes in slope conductance of 5-HT1A
Fig 3. Antagonism at α1-adrenoceptors by trazodone contributes in the inhibition of serotonergic neuron activity.
(A) Representative recording of neuron activity facilitated by 1 μM phenylephrine (PE) in the presence of Way-100635
(+Way; 20 nM). The inhibitory effect of 10 μM trazodone (TZD) is surmounted by addition of 100 μM phenylephrine
(PE). (B) Summary of five experiments (mean ± SD; One-way RM ANOVA: F(2,4) = 48.74; p<0.0002). (C)
Representative recording of the concentration-dependent effect of trazodone on neuron activity facilitated by low
calcium ACSF (see methods) in the absence of PE. (D) Summary of five experiments (mean ± SD; One-way RM
ANOVA: F(2,4) = 16.21; p<0.0122)
� p< 0.05; �� p< 0.01; ��� p< 0.001 (One-Way RM ANOVA followed by Tukey
post-hoc test).
https://doi.org/10.1371/journal.pone.0222855.g003
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receptor-coupled GIRK channels, which provided a direct measure of 5-HT1A receptor activa-
tion produced by the application of trazodone. As illustrated in Fig 6, the concentration-
dependent effect of trazodone (1–30 μM; n = 12) was maximal at 30 μM and was reversed by
Fig 4. Block of 5-HT1A receptors by Way-100635 uncovers the α1-adrenoceptor- dependent effect of trazodone. (A) Representative experiment
showing the effect of trazodone (TZD) on neuron firing facilitated by 1 μM phenylephrine (PE) in the presence of Way-100635 (20 nM). (B) DRC resulting
from the experiment shown in (A). Red line is the best least-squares fit to the logistic equation. (C) Scatter plot of the individual EC50 values calculated
from fifteen similar experiments. (D) Representative experiment showing the effect of trazodone on neuron firing facilitated by 10 μM PE (E) DRC
resulting from the experiment shown in (D). Red line is the best least-squares fit to the logistic equation. Note that 30 μM trazodone is required to silence
the neuron. (F) Scatter plot of the individual EC50 values calculated from eleven experiments. (G) Representative recording from a set of experiments
(n = 9) in which trazodone 10 μM and 30 μM was applied in the presence of 100 μM PE. In (B) and (E), dotted line indicates the baseline (Bsl) firing rate
before application of trazodone. In (C) and (F), red line and error bars indicate the geometric mean and 95% C.I. (H) Average DRCs of trazodone effect
obtained from the experiments in PE 1–100 μM. Symbols and error bars correspond to the mean values± SD obtained for each concentration in the
corresponding set of experiments. Red line is the best least-squares fit to the logistic equation. Data are normalized on average baseline firing rates
recorded before trazodone application. The baseline firing rates of neurons recorded in the three groups were (Hz, mean ± SD): 1.840 ± 0.5444 in PE 1μM
(n = 15), 1.766 ± 0.4040 in PE 10μM (n = 11) and 1.970 ± 0.5559 in PE 100 μM (n = 9). These values were not significantly different (F(2.32) = 0.4046;
p = 0.6706; One-Way ANOVA).
https://doi.org/10.1371/journal.pone.0222855.g004
Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons
PLOS ONE | https://doi.org/10.1371/journal.pone.0222855 September 26, 2019 10 / 19
the application of the selective 5-HT1A receptor antagonist Way-100635. In nine out twelve
recorded neurons, the magnitude of the concentration-dependent increases in GIRK channel
conductance permitted reliable fitting of data in individual concentration-response curves.
The average EC50 value for GIRK channel opening by trazodone obtained from individual
neurons was 3.34 μM (Geometric mean, 95% C.I.: 2.21–5.06; n = 9; Fig 6B).
To quantify the efficacy of trazodone at 5-HT1AARs, we compared the effect of the maxi-
mally active concentration of trazodone with that of the 5-HT1A receptor full agonist 5-CT in
the same neurons. In all recordings in which 5-CT (30 nM) and trazodone (30 μM) were
applied in the same neurons 5-CT produced an increase in GIRK channel conductance greater
than that of trazodone (n = 14; Fig 6C) whose effect was occasionally very small (n = 3). From
the peak effects produced by trazodone and 5-CT the calculated average efficacy of trazodone
compared to 5-CT was 35.3% (Fig 6D; paired t test, two tails: t = 6.588; df = 13; p< 0.0001;
n = 14). To confirm these findings in a larger number of neurons and to further ensure that
the application of 5-CT in the same neuron did not change the sensitivity to trazodone action
at 5-HT1AARs, we compared the response to single applications of 5-CT and trazodone in dif-
ferent neurons. As the magnitude of GIRK conductance responses to trazodone appeared cor-
related to cell membrane capacitance (Fig 6E), which reflects the surface area of recorded
neurons, the effects of trazodone and 5-CT were normalized to the membrane capacitance to
Fig 5. Activation of 5-HT1A receptors by trazodone in high phenylephrine. (A, B) Representative recordings of potent (A)
and weak (B) trazodone (TZD effects on serotonergic neuron firing in the presence of 100 μM phenylephrine. Note that
trazodone effect in (A) was fully antagonized by 20 nM Way-100635 (Way). (C) Average DRC obtained from all the
experiments (n = 11). (D) Summary scatter plot of individual EC50 values from experiments in which complete DRC were
obtained (n = 8). Data are normalized on Bsl firing rate. Red line is the best least-squares fit to the logistic equation. Symbols
and error bars report the mean value ± SD. (E) Summary of the antagonism of Way-100635 on trazodone 10 μM (mean ± SD;
n = 7; One-way RM ANOVA: F(2,6) = 11.80; p<0.0015).
�p< 0.05, ��p< 0.01 (One-Way RM ANOVA followed by a Tukey
post-hoc test).
https://doi.org/10.1371/journal.pone.0222855.g005
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Fig 6. Trazodone partially activates 5-HT1A receptor-coupled GIRK channels of serotonergic neurons. (A) Concentration-response
relationship for 5-HT1AAR-mediated activation of GIRK conductance by trazodone. Left panel: Time-course of a representative
experiment showing the effect of increasing concentrations of bath-applied trazodone (TZD) on GIRK conductance (G-110/-85 mV) in a
serotonergic neuron. G-110/-85 mV was measured as the slope conductance activated in the range from -110 to -85 mV membrane
potential by hyperpolarizing ramps under whole-cell voltage-clamp (see methods). Application of the selective 5-HT1A receptor
antagonist Way-100635 (20 nM) reveals the 5-HT1A receptor-mediated component of the response. Time indicates duration of whole-
cell configuration. Right panel: concentration-response relationship of the same experiment. The red line is the best least-squares fit to
the logistic equation. (B) Scatter plot of EC50 values of trazodone in individual neurons (n = 9). Note the ordinate in logarithmic scale.
Bars correspond to geometric mean ± 95% C.I. (C) Left panel: Time-course of a representative experiment performed to compare the
maximal effect of trazodone (30 μM) with that of the full agonist 5-CT (30 nM) on GIRK conductance (G-110/-85 mV) in a serotonergic
neuron. Right panel: Current-voltage plot of agonist-induced currents of the same experiment. Each trace is the difference between
current in the presence of the indicated agonist and control current recorded before the agonist application. (D) Left graph:
Comparison of 30 μM trazodone and 30 nM 5-CT effects in individual neurons. Right graph: Scatter plot summarizing the extent of
trazodone partial agonism in individual recordings (100 x G-110/-85 mV, TZD / G-110/-85 mV, 5-CT). Bars correspond to mean ± SD. (E) The
correlation between the effect of 30 μM trazodone (G-110/-85 mV) and the cell membrane capacitance (CCell). Symbols represent single
experiments (n = 34). Red line represents best least square fit. Correlation analysis revealed moderate positive correlation (Pearson
r = 0.38, p = 0.026). (F) Comparison of 30 μM trazodone (n = 34) and 30 nM 5-CT (n = 68) effects in serotonergic neuron population.
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correct for differences in cell size and density of GIRK channels in different neurons. The max-
imal trazodone effect was 29.12 ± 19.63 (pS/pF; n = 34) and resulted significantly smaller com-
pared to that produced by 5-CT (86.68 ± 33.12 pS/pF; n = 68; unpaired t test two tails,
t = 9.333; df = 100; p< 0.0001; Fig 6F). The resulting mean efficacy of trazodone was of 33.6%
compared to that of 5-CT, a value very similar to that found when the two compounds were
applied in the same neurons.
The weak partial agonism by trazodone partially antagonizes full agonist
action of 5-CT at 5-HT1A autoreceptors
The weak efficacy of trazodone suggested that the drug could exert a competitive antagonism
of the response to the full agonist 5-CT. We therefore compared the response to 10 nM 5-CT
applied alone or in the presence of 10 μM trazodone. We have chosen submaximal concentra-
tions of the two drugs so that eventual summation of the two effects could be revealed. As illus-
trated in Fig 7, comparison of peak effects produced by 5-CT alone or in the presence of
trazodone (4.21 ± 1.66 vs 2.42 ± 1.29 nS; Fig 7B; n = 5; paired t test, two tails: t = 6.675; df = 4;
p = 0.0026) shows that the total activation of the GIRK conductance resulting by coapplication
of 5-CT and trazodone was smaller (54.8 ± 11.4%, n = 5, Fig 7C) than that measured when
5-CT was applied alone in the same neurons.
The quantification of the agonist efficacy of trazodone at 5-HT1AARs provided a measured
value for a theoretical estimate of 5-HT1AAR activation in the absence of trazodone and in the
presence of the drug [35] (see methods). The calculated response to 10 nM 5 CT in the pres-
ence of 10 μM trazodone (42.2% of maximal response produced by 5 CT) was not statistically
different from that reported in Fig 7C (54.8 ± 11.4%, n = 5; p = 0.125 Wilcoxon signed rank
test).
These results show that trazodone is able to significantly decrease the activation of
5-HT1AARs produced by the full agonist 5-CT and confirmed the applicability of the measured
efficacy value to estimate the effects of different trazodone concentrations on the total
5-HT1AAR activation by a full agonist using the known affinity constants of the agonists.
Discussion
Trazodone displays relatively high affinity for several proteins involved in the direct or indirect
regulation of serotonergic neuron activity, including 5-HT1A receptors, α1-adrenoceptors and
SERT [5]. The present study elucidates how the binding of trazodone at these sites translates
into direct changes of serotonergic neuron activity. In particular, we characterized the proper-
ties of 5-HT1AAR activation by trazodone and the relevance of α1-adrenoceptor antagonism
in the overall effect of the drug on serotonergic neuron activity. The data reported herein dem-
onstrate that trazodone is an α1-adrenoceptor antagonist and a weak partial agonist at
5-HT1AARs of DRN serotonergic neurons. Functionally, these two independent actions con-
verge in inhibiting the activity of serotonergic neurons with variable contribution according to
the noradrenergic drive elicited by PE in vitro and, presumably, to the arousal state in vivo.
The activity of serotonergic neurons is physiologically facilitated by noradrenergic tone
which varies during the sleep-wake cycle, being maximal during wake [36]. At the same time
the extracellular 5-HT present in the raphe tonically stimulates 5-HT1AARs thereby limiting
neuron firing [37, 38, 12]. The latter action is greatly enhanced when the reuptake of 5-HT is
Data are normalized for cell membrane capacitance. Symbols represent the response of individual neurons to single applications of
5-HT1A receptor agonists. Bars correspond to mean ± SD.
https://doi.org/10.1371/journal.pone.0222855.g006
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inhibited by antidepressant drugs. This effect is believed to result in a therapeutically inappro-
priate limitation of serotonergic neuron activity for some weeks, until 5-HT1AAR desensitiza-
tion occurs [13, 14] or other compensatory mechanisms reconduct serotonergic neuron firing
to normal rate in spite of active autoinhibition [39].
Trazodone inhibits the firing of serotonergic neurons recorded from the DRN in anaesthe-
tized rats [19] through an action involving 5-HT1A receptor activation [20]. However, in vivo
studies did not fully elucidate whether the firing suppression was due to direct activation of
5-HT1AARs, increase in extracellular 5-HT due to SERT inhibition, α1-adrenoceptor antago-
nism, or a combination of these effect. Our experiments show that trazodone directly activates
Fig 7. Antagonism at 5-HT1A autoreceptors by trazodone. (A) Time-course of a representative experiment in a
serotonergic neuron showing that the total activation of the GIRK conductance (G-110/-85 mV) produced by 10 nM
5-CT in the presence of 10 μM trazodone (TZD) is smaller than that measured when 5-CT is applied alone. (B)
Comparison of 10 nM 5-CT effects in control and in the presence of 10 μM trazodone in individual neurons (n = 5).
(C) Scatter plot summarizing the antagonism of 5-CT effect exerted by trazodone at 5-HT1AARs in five experiments.
Values are calculated on net 5-HT1A receptor-activated GIRK conductance obtained from data shown in (B) after
baseline conductance subtraction. Bars correspond to mean ± SD. ��p< 0.01 (paired t test, two tails).
https://doi.org/10.1371/journal.pone.0222855.g007
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5-HT1AARs since the effect of the drug was not modified when the local action of the major
neurotransmitters was prevented by selective antagonists. Furthermore, the 5-HT1A receptor-
mediated inhibition of firing was present in Tph2-/- mice that lack brain 5-HT indicating that
this effect of trazodone was not mediated by endogenous 5-HT acting on serotonergic or
neighbour neurons.
In our extracellular recordings the firing of serotonergic neurons was facilitated by the
stimulation of α1-adrenoceptors with PE to reproduce the activation of serotonergic neurons
by noradrenergic drive in vivo [40]. Therefore, although in our in vitro conditions disfacilita-
tion of firing due to α1-adrenoceptor antagonism by trazodone resulted additive to the 5-HT1A
receptor-mediated inhibitory effect, these two components of trazodone action could be
pharmacologically better discriminated than in vivo models. Thus, in the presence of the selec-
tive 5-HT1A receptor antagonist Way-100635 the effect of trazodone was concentration-
dependently surmounted by increasing PE, indicating that trazodone is a competitive antago-
nist at α1-adrenoceptors. Consistently, when serotonergic neuron firing was facilitated by low-
ering Ca2+ content in the ACSF in the absence of PE, trazodone silenced serotonergic neuron
firing and the effect was fully antagonized by Way-100635. Furthermore, when the effect of α1-
adrenoceptor antagonism by trazodone was minimized by the presence of high PE the 5-HT1A
receptor-mediated inhibition persisted, although efficacy was much weaker, suggesting that
trazodone is a partial agonist at 5-HT1AARs.
The partial agonism of trazodone at 5-HT1AARs was confirmed by means of whole-cell
recording in which we quantified the net increase in serotonergic neuron membrane conduc-
tance produced by the opening of GIRK channels in response to the drug in the absence of PE.
The amount of activated GIRK channels is proportional to the number of receptors stimulated,
thus GIRK conductance reliably reports the concentration-dependent effect of agonists allow-
ing for quantitative evaluation of the potency and intrinsic efficacy of trazodone at
5-HT1AARs.
The efficacy of trazodone in activating 5-HT1AARs was about one third of that of the full
agonist 5-CT with a potency in the low micromolar range, hence this action would occur at
therapeutic concentrations of the drug [41]. The weak efficacy of trazodone in activating
5-HT1AARs is consistent with data obtained using 5-HT1A receptor-stimulated [
35S]-GTPγS
binding in rat hippocampal and cortical membrane preparations (� 20% at 30 μM) [21]).
We also show that the weak intrinsic activity of trazodone exerts partial antagonism of the
action of the full agonist 5-CT. Thus, at therapeutic concentrations the weak partial agonism
of trazodone could antagonize the full activation of 5-HT1AARs of endogenous 5-HT, whose
extracellular concentration is raised by the concomitant block of SERT produced by
trazodone.
Notably, the partial antagonism exerted by trazodone does not prevent 5-HT1AAR desensi-
tization during treatment in vivo (20). This is in agreement with the effect of other partial ago-
nists [42], whereas full antagonists have been shown to prevent functional desensitization of
5-HT1AARs (e.g. Way-100635 [43].
Notwithstanding the more complex effects that trazodone can produce in vivo through its
action at other receptors (e.g. 5-HT2A) or local/long-loop feedback regulation, our data pro-
vide the ground for mechanistic interpretation of the interplay between the 5-HT1A receptor
agonist and α1-adrenoceptor antagonist properties of trazodone in directly regulating seroto-
nergic neuron firing.
Trazodone exerted functionally considerable effects on both 5-HT1AARs and α1-adreno-
ceptors at concentrations� 3 μM that are relevant to the clinical effects of the drug when used
as antidepressant or off label hypnotic. One single oral dose of 300 mg trazodone-ER
(extended release) produces stable plasma concentrations of ~3 μM for 12 h in healthy
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volunteers [44]. At this concentration, trazodone would weakly activate 5-HT1AARs but, at the
same time, would substantially antagonize the full activation of 5-HT1AARS by 5-HT whose
level is raised by the block of SERT produced by the drug. In humans, assuming that the basal
extracellular concentration of 5-HT in DRN is similar to that measured in the rat in vivo (~10
nM) [45] and that trazodone produces a fivefold increase in 5-HT extracellular level [46]), at
therapeutic concentrations achievable in the brain (3 μM) the relative occupancy at
5-HT1AARs by trazodone and 5-HT would be ~70% and ~30% respectively (see methods).
Under these conditions the total activation of 5-HT1AARs will be ~52% of that produced by 50
nM 5-HT in the absence of the weak partial agonist trazodone.
Interestingly, Ghanbari et al. [20] reported that the basal firing rate in vivo after two days of
treatment with trazodone was decreased by ~40% compared to controls. This is a relatively
weaker inhibition than that observed in similar conditions with escitalopram (~ 70%) [47],
although results are from two separate experimental setting, hence not directly comparable.
Importantly, the antagonist effect of trazodone would occur starting from the first drug
administration. This would limit the detrimental tonic inhibition of serotonergic neuron firing
produced by the raise in extracellular 5-HT starting from the beginning of the therapy, regard-
less the mechanism(s) involved in the recovery of neuron activity during chronic treatment
with antidepressant drugs [13, 14, 39]. Recently, it has been proposed that faster and/or better
clinical response to treatment could be achieved with antidepressant drugs that combine SERT
inhibition with 5-HT1A receptor partial agonism [18]. In agreement with this hypothesis, clini-
cal signs of antidepressant effect were detected after one week of treatment with trazodone
[48]).
Among antidepressant drugs trazodone has a distinctive sleep regulating activity [49]) that
favoured its off-label use in insomnia [7]. The 5-HT system participates in arousal and is impli-
cated in sleep, being active during waking and becoming progressively inactive during slow
wave sleep and almost completely silent during REM sleep [9, 50, 51, 3]. These state dependent
changes in activity of 5-HT system can be ascribed, at least in part, to similar changes in norad-
renergic neuron activity [52], that facilitate the firing of serotonergic neurons via activation of
α1-adrenoceptors [25].
Although the relative contribution of 5-HT1A and α1-adrenoceptor effects in vivo cannot be
fully mimicked in vitro as the actual degree of noradrenergic drive changes during wake-sleep
cycle, the combined 5-HT1A receptor agonist and α1-adrenoceptor antagonist effects of trazo-
done on these neurons could be relevant to its effects on sleep. At concentrations akin those
present in human brain following administration of trazodone for sleep disorders [41], the
dual action of trazodone could facilitate inhibition of serotonergic neuron firing in the phase
of drowsiness when α1-adrenoceptor stimulation is lowered [53]. In addition, antagonism at
α1-adrenoceptor is likely to dampen the effects of noradrenergic system reactivation that
occurs during sleep thereby preventing insomnia-related microarousals [54].
In conclusion, our results show that trazodone directly inhibits DRN serotonergic neuron
activity through 5-HT1A receptor weak partial agonism and α1-adrenoceptor antagonism. Col-
lectively our data suggest that the overall inhibition of neuron activity produced by the dual
action of trazodone will result inversely proportional to the degree of α1-adrenoceptor activa-
tion, being maximal when α1-adrenoceptor is low and gradually decreasing with higher α1-
adrenoceptor stimulation.
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